Palobiofarma SL
10
0
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.0%
1 terminated/withdrawn out of 10 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Therapeutic Effect of PBF-680 in Patients With COPD
Role: lead
PBF-1129 in Patients With NSCLC
Role: lead
Study of PBF-999 in Solid Tumour Advanced Cancer
Role: lead
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
Role: lead
Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Role: lead
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
Role: lead
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
Role: lead
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Role: lead
"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers
Role: lead
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
Role: lead
All 10 trials loaded